Full text
PDF
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Arnaud J. P., Buyse M., Nordlinger B., Martin F., Pector J. C., Zeitoun P., Adloff A., Duez N. Adjuvant therapy of poor prognosis colon cancer with levamisole: results of an EORTC double-blind randomized clinical trial. Br J Surg. 1989 Mar;76(3):284–289. doi: 10.1002/bjs.1800760322. [DOI] [PubMed] [Google Scholar]
- Buyse M., Zeleniuch-Jacquotte A., Chalmers T. C. Adjuvant therapy of colorectal cancer. Why we still don't know. JAMA. 1988 Jun 24;259(24):3571–3578. [PubMed] [Google Scholar]
- Chlebowski R. T., Lillington L., Nystrom J. S., Sayre J. Late mortality and levamisole adjuvant therapy in colorectal cancer. Br J Cancer. 1994 Jun;69(6):1094–1097. doi: 10.1038/bjc.1994.214. [DOI] [PMC free article] [PubMed] [Google Scholar]
- De Brabander M., De Crée J., Vandebroek J., Verhaegen H., Janssen P. A. Levamisole in the treatment of cancer: anything new? (Review). Anticancer Res. 1992 Jan-Feb;12(1):177–187. [PubMed] [Google Scholar]
- Goodrich K. H., Alvarez X., Holcombe R. F. Effect of levamisole on major histocompatibility complex class I expression in colorectal and breast carcinoma cell lines. Cancer. 1993 Jul 1;72(1):225–230. doi: 10.1002/1097-0142(19930701)72:1<225::aid-cncr2820720140>3.0.co;2-y. [DOI] [PubMed] [Google Scholar]
- Janik J., Kopp W. C., Smith J. W., 2nd, Longo D. L., Alvord W. G., Sharfman W. H., Fenton R. G., Sznol M., Steis R. G., Creekmore S. P. Dose-related immunologic effects of levamisole in patients with cancer. J Clin Oncol. 1993 Jan;11(1):125–135. doi: 10.1200/JCO.1993.11.1.125. [DOI] [PubMed] [Google Scholar]
- Kimmel D. W., Schutt A. J. Multifocal leukoencephalopathy: occurrence during 5-fluorouracil and levamisole therapy and resolution after discontinuation of chemotherapy. Mayo Clin Proc. 1993 Apr;68(4):363–365. doi: 10.1016/s0025-6196(12)60132-3. [DOI] [PubMed] [Google Scholar]
- Laurie J. A., Moertel C. G., Fleming T. R., Wieand H. S., Leigh J. E., Rubin J., McCormack G. W., Gerstner J. B., Krook J. E., Malliard J. Surgical adjuvant therapy of large-bowel carcinoma: an evaluation of levamisole and the combination of levamisole and fluorouracil. The North Central Cancer Treatment Group and the Mayo Clinic. J Clin Oncol. 1989 Oct;7(10):1447–1456. doi: 10.1200/JCO.1989.7.10.1447. [DOI] [PubMed] [Google Scholar]
- Moertel C. G., Fleming T. R., Macdonald J. S., Haller D. G., Laurie J. A., Goodman P. J., Ungerleider J. S., Emerson W. A., Tormey D. C., Glick J. H. Levamisole and fluorouracil for adjuvant therapy of resected colon carcinoma. N Engl J Med. 1990 Feb 8;322(6):352–358. doi: 10.1056/NEJM199002083220602. [DOI] [PubMed] [Google Scholar]
- Moertel C. G., Fleming T. R., Macdonald J. S., Haller D. G., Laurie J. A. Hepatic toxicity associated with fluorouracil plus levamisole adjuvant therapy. J Clin Oncol. 1993 Dec;11(12):2386–2390. doi: 10.1200/JCO.1993.11.12.2386. [DOI] [PubMed] [Google Scholar]
- Stevenson H. C., Green I., Hamilton J. M., Calabro B. A., Parkinson D. R. Levamisole: known effects on the immune system, clinical results, and future applications to the treatment of cancer. J Clin Oncol. 1991 Nov;9(11):2052–2066. doi: 10.1200/JCO.1991.9.11.2052. [DOI] [PubMed] [Google Scholar]
- Wolmark N., Rockette H., Fisher B., Wickerham D. L., Redmond C., Fisher E. R., Jones J., Mamounas E. P., Ore L., Petrelli N. J. The benefit of leucovorin-modulated fluorouracil as postoperative adjuvant therapy for primary colon cancer: results from National Surgical Adjuvant Breast and Bowel Project protocol C-03. J Clin Oncol. 1993 Oct;11(10):1879–1887. doi: 10.1200/JCO.1993.11.10.1879. [DOI] [PubMed] [Google Scholar]